ID   MDA-MB-134-VI
AC   CVCL_0617
SY   MDA-MB-134 VI; MDA MB 134VI; MDA-MB-134VI; MDAMB134VI; MDA-MB-134; MDAMB134; MDA-134; MDA134; MM134; MD Anderson-Metastatic Breast-134-VI
DR   CLO; CLO_0007631
DR   EFO; EFO_0001205
DR   CLDB; cl3398
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-TABM-157
DR   ATCC; HTB-23
DR   BioSample; SAMN03471473
DR   BioSample; SAMN10988465
DR   cancercelllines; CVCL_0617
DR   CCRID; 1101HUM-PUMC000380
DR   Cell_Model_Passport; SIDM00005
DR   ChEMBL-Cells; CHEMBL3308340
DR   ChEMBL-Targets; CHEMBL2366242
DR   Cosmic; 687491
DR   Cosmic; 735125
DR   Cosmic; 809233
DR   Cosmic; 904374
DR   Cosmic; 908119
DR   Cosmic; 934525
DR   Cosmic; 997933
DR   Cosmic; 1000129
DR   Cosmic; 1046947
DR   Cosmic; 1047696
DR   Cosmic; 1090333
DR   Cosmic; 1136347
DR   Cosmic; 1152519
DR   Cosmic; 1287908
DR   Cosmic; 1289392
DR   Cosmic; 1603216
DR   DepMap; ACH-000044
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 908119
DR   GEO; GSM115107
DR   GEO; GSM186432
DR   GEO; GSM186433
DR   GEO; GSM186434
DR   GEO; GSM217584
DR   GEO; GSM219959
DR   GEO; GSM320180
DR   GEO; GSM350523
DR   GEO; GSM421870
DR   GEO; GSM783960
DR   GEO; GSM847398
DR   GEO; GSM847491
DR   GEO; GSM887292
DR   GEO; GSM888367
DR   GEO; GSM1053695
DR   GEO; GSM1172976
DR   GEO; GSM1172886
DR   GEO; GSM1215268
DR   GEO; GSM1226522
DR   GEO; GSM1226523
DR   GEO; GSM1226524
DR   GEO; GSM1226525
DR   GEO; GSM1226526
DR   GEO; GSM1226527
DR   GEO; GSM1226528
DR   GEO; GSM1226529
DR   GEO; GSM1226530
DR   GEO; GSM1226531
DR   GEO; GSM1226532
DR   GEO; GSM1226533
DR   GEO; GSM1226534
DR   GEO; GSM1226535
DR   GEO; GSM1226536
DR   GEO; GSM1226537
DR   GEO; GSM1226538
DR   GEO; GSM1226539
DR   GEO; GSM1226540
DR   GEO; GSM1226541
DR   GEO; GSM1238133
DR   GEO; GSM1374647
DR   GEO; GSM1401662
DR   GEO; GSM1661981
DR   GEO; GSM1670078
DR   IARC_TP53; 18375
DR   IZSLER; BS TCL 236
DR   LiGeA; CCLE_784
DR   LINCS_HMS; 50327
DR   LINCS_LDP; LCL-1316
DR   PharmacoDB; MDAMB134VI_897_2019
DR   Progenetix; CVCL_0617
DR   PubChem_Cell_line; CVCL_0617
DR   SLKBase; 3582
DR   Wikidata; Q54904577
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   DOI=10.25904/1912/1434;
RX   PubMed=730202;
RX   PubMed=833871;
RX   PubMed=3518877;
RX   PubMed=4412247;
RX   PubMed=6220172;
RX   PubMed=7842014;
RX   PubMed=9331070;
RX   PubMed=9671407;
RX   PubMed=10862037;
RX   PubMed=10969801;
RX   PubMed=11044355;
RX   PubMed=11343771;
RX   PubMed=12353263;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=20164919;
RX   PubMed=22460905;
RX   PubMed=23601657;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=24425047;
RX   PubMed=25485619;
RX   PubMed=25757734;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=28196595;
RX   PubMed=28889351;
RX   PubMed=30228172;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://www.cellosaurus.org/pawefish/BreastCellLineDescriptions/mda-mb-134.htm
WW   https://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: FGFR genetic alteration cell panel (ATCC TCP-1034).
CC   Part of: JWGray breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Caucasian.
CC   Doubling time: 6.4 days (PubMed=9671407); 82.67 hours (JWGray panel).
CC   HLA typing: A*11:02,24:02; B*35:01,40:01; C*03:04,04:01; DQB1*03:02,06:02; DRB1*13:27,13:27 (PubMed=25960936).
CC   HLA typing: A*11:01,24:02; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Leu230fs*4 (c.688_832del145); Zygosity=Homozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=19593635).
CC   Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Ser184Leu (c.551C>T); Zygosity=Homozygous (PubMed=9331070; PubMed=19593635; DepMap=ACH-000044).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=16541312).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=2.96%; Native American=0%; East Asian, North=3.67%; East Asian, South=0%; South Asian=0%; European, North=64.3%; European, South=29.06% (PubMed=30894373).
CC   Misspelling: MDA-MB-134IV; Cosmic=1000129.
CC   Misspelling: MDA-MB-134-IV; Cosmic=1090333; PubMed=9331070.
CC   Misspelling: MDA-MD-134VI; PubMed=16541312.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): ATCC=HTB-23; CCRID=1101HUM-PUMC000380; PubMed=25877200; PubMed=28889351
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 8
ST   D16S539: 13
ST   D18S51: 10,16
ST   D19S433: 13,15
ST   D21S11: 26,28
ST   D2S1338: 17,18
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 14
ST   FGA: 21,22
ST   Penta D: 12,13
ST   Penta E: 7,9
ST   TH01: 6,9
ST   TPOX: 8,11
ST   vWA: 14,15
DI   NCIt; C7950; Invasive breast lobular carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   47Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 43
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
//
RX   DOI=10.25904/1912/1434;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010); Griffith University; Brisbane; Australia.
//
RX   PubMed=730202; DOI=10.1007/BF02616120;
RA   Cailleau R.M., Olive M., Cruciger Q.V.J.;
RT   "Long-term human breast carcinoma cell lines of metastatic origin:
RT   preliminary characterization.";
RL   In Vitro 14:911-915(1978).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=4412247; DOI=10.1093/jnci/53.3.661; PMCID=PMC7364228;
RA   Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.;
RT   "Breast tumor cell lines from pleural effusions.";
RL   J. Natl. Cancer Inst. 53:661-674(1974).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=7842014; DOI=10.1038/ng1094-155;
RA   Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.;
RT   "Identification of cryptic sites of DNA sequence amplification in
RT   human breast cancer by chromosome microdissection.";
RL   Nat. Genet. 8:155-161(1994).
//
RX   PubMed=9331070;
RA   Teng D.H.-F., Perry W.L. 3rd, Hogan J.K., Baumgard M.L., Bell R.,
RA   Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R.,
RA   Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R.,
RA   Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M.,
RA   Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A.,
RA   Skolnick M.H., Tavtigian S.V.;
RT   "Human mitogen-activated protein kinase kinase 4 as a candidate tumor
RT   suppressor.";
RL   Cancer Res. 57:4177-4182(1997).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B;
RA   Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F.,
RA   Isola J.J., Larsson C.;
RT   "Chromosomal alterations in 15 breast cancer cell lines by comparative
RT   genomic hybridization and spectral karyotyping.";
RL   Genes Chromosomes Cancer 28:308-317(2000).
//
RX   PubMed=10969801;
RA   Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y.,
RA   Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.;
RT   "Comparative genomic hybridization analysis of 38 breast cancer cell
RT   lines: a basis for interpreting complementary DNA microarray data.";
RL   Cancer Res. 60:4519-4525(2000).
//
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458; PMCID=PMC2408781;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
//
RX   PubMed=11343771; DOI=10.1016/S0165-4608(00)00387-3;
RA   Rummukainen J., Kytola S., Karhu R., Farnebo F., Larsson C.,
RA   Isola J.J.;
RT   "Aberrations of chromosome 8 in 16 breast cancer cell lines by
RT   comparative genomic hybridization, fluorescence in situ
RT   hybridization, and spectral karyotyping.";
RL   Cancer Genet. Cytogenet. 126:1-7(2001).
//
RX   PubMed=12353263; DOI=10.1002/gcc.10107;
RA   Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J.,
RA   Mozziconacci M.-J., Conte N., Murati A., Ginestier C.,
RA   Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C.,
RA   Birnbaum D., Chaffanet M.;
RT   "Reciprocal translocations in breast tumor cell lines: cloning of a
RT   t(3;20) that targets the FHIT gene.";
RL   Genes Chromosomes Cancer 35:204-218(2002).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G.,
RA   den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33.1-R33.17(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M.,
RA   Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J.,
RA   Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=24425047; DOI=10.1158/0008-5472.CAN-13-2779; PMCID=PMC3955299;
RA   Sikora M.J., Cooper K.L., Bahreini A., Luthra S., Wang G.-Y.,
RA   Chandran U.R., Davidson N.E., Dabbs D.J., Welm A.L., Oesterreich S.;
RT   "Invasive lobular carcinoma cell lines are characterized by unique
RT   estrogen-mediated gene expression patterns and altered tamoxifen
RT   response.";
RL   Cancer Res. 74:1463-1474(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25757734; DOI=10.1186/s13058-015-0517-z; PMCID=PMC4320436;
RA   Christgen M., Derksen P.W.B.;
RT   "Lobular breast cancer: molecular basis, mouse and cellular models.";
RL   Breast Cancer Res. 17:16.1-16.9(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=30228172; DOI=10.1158/0008-5472.CAN-18-1416; PMCID=PMC6507416;
RA   Tasdemir N., Bossart E.A., Li Z.-Q., Zhu L., Sikora M.J., Levine K.M.,
RA   Jacobsen B.M., Tseng G.C.-C., Davidson N.E., Oesterreich S.;
RT   "Comprehensive phenotypic characterization of human invasive lobular
RT   carcinoma cell lines in 2D and 3D cultures.";
RL   Cancer Res. 78:6209-6222(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//